Parkinson s Disease and Treatment Options for the Younger Adult

Size: px
Start display at page:

Download "Parkinson s Disease and Treatment Options for the Younger Adult"

Transcription

1 Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had Tremor of her right hand off and on for 3 months Tremor mainly while reading or watching television Handwriting has become small Trouble beating an egg with her right hand Her family had noted A loss of facial expression She doesn t swing her right arm when she walks Case Presentation - 2 On exam, she showed Reduced blinking and facial expression Soft, monotonous voice General lack of movement Activated rigidity in the right upper limb Slowness of repetitive movements with the right hand Tremor of the right hand when she walks

2 James Parkinson s monograph Core clinical features: Tremor Rigidity Akinesia Postural disturbances Tremor Rest tremor (characteristic) Occurs in repose 3-7 Hz (slow) TIP: Watch for rest tremor while walking, or during tasks of concentration (e.g., arithmetic, reciting months backward) Action tremor (less common) Occurs with muscle activation 6-11 Hz (fast) Rigidity Muscle tone: Increased passive resistance A sign clinicians elicit, not a symptom Unlike spasticity, uniform in antagonists, throughout a joint range, regardless of speed TIP: Accentuated by contralateral activity Cogwheeling : correlated with tremor, not rigidity

3 Akinesia Akinesia : from the Greek for lack of movement Impairment of voluntary movement Typically causes most of the disability in PD Akinesia 3 components: Bradykinesia (decreased speed of movement) e.g. Slow initiation and execution of all movement Hypokinesia (decreased amplitude of movement) e.g. Micrographia, decreased arm swing, short stride Oligokinesia (decreased quantity of movement) e.g. Reduced blink and facial expression TIP: Tendency to progressive fatigue with repetition Micrographia

4 Postural Disturbances Flexion posture Disorder of equilibrium Exam: Test for retropulsion Pull backward on shoulders Normal: recover balance in 2 steps Parkinsonism vs. Parkinson s Parkinsonism a syndrome consisting of Tremor Rigidity Akinesia Postural disturbances Parkinsonism vs. Parkinson s Parkinson s Disease A degenerative disease with characteristic motor and non-motor clinical features, epidemiology, evolution, prognosis, treatment and pathology Parkinson s disease is the most common cause of parkinsonism, but not the only cause

5 Non-Motor Features Cognitive (dementia, excess somnolence) Autonomic (constipation, orthostatic hypotension, incontinence, sexual or sweat dysfunction) Sensory (restless legs, loss of smell) Miscellaneous (depression, REM-sleep behavior disorder) Premotor Features May precede motor onset by decades Strongest evidence established for: Olfactory deficit Constipation REM-sleep behavior disorder Excess daytime somnolence Depression, anxiety Savica et al. Arch Neurol 2010; 67: Lang. Mov Disord 2011; A Redefinition of PD Preclinical PD Pathology present; no clinical findings Premotor PD Early non-motor symptoms and signs Motor PD Classic motor manifestations Stern M, et al. Mov Disord 2012; 27: 54-60

6 Epidemiology Affects approximately 1 million patients in USA Prevalence: 0.3% of general population 1-3% of those older than 65 years Average age of onset is 60 years most notice first symptoms in their 50s or 60s ~5% of PD patients develop first symptoms before age 40, ~15% before age 50 ( young-onset PD, or YOPD) Typical Clinical Course Starts in one limb Dominant:non-dominant = 3:2 Progresses slowly over months and years Typically first to the other limb on the same side Eventually becomes bilateral, but remains worse on the side first affected Tremor, rigidity and akinesia early; postural instability late Etiology Multiple gene mutations now associated with PD Genetic factors play a larger role in patients with young-onset PD Environmental insults probably play a role in patients with PD onset after age 50 Excessive protein ( -synuclein) accumulation is found in all cases of PD

7 How is PD different for younger adults? Definition of young-onset PD Usually defined as onset < 40 or < 50 years But definitions vary widely Here I use < 50 years old, unless stated Etiology: More frequent (+) family history Onset < 50: risk of PD in sibs Sibs at risk of also developing PD < 50 y.o. Barrett et al. Mov Disord 2015; 30: How is PD different for younger adults? Delayed diagnosis of PD with onset < 45 y.o. Mean 15 additional months until diagnosis in PD patients Higher number of visits to neurologists prior to dx Higher number of lab investigations prior to dx Rana et al. J Neurol Sci 2012; 323: Usually need care beyond initial doctor s career How is PD different for younger adults? Course: Progression is slower Mortality Life expectancy (LE) closer to normal in relative, but not absolute, terms e.g., onset age 25-39: lose 22% LE, or 11 years; onset age > 64: lose 44% LE, or 4 years Wickremaratchi et al. Eur J Neurol 2009; 16: 450 6

8 How is PD different for younger adults? Increased rates of: onset with non-tremor symptom dystonia (at onset or during treatment) levodopa-induced dyskinesias depression, anxiety Clinical manifestations and complications: Lower rates of early gait difficulty falls, freezing dementia autonomic disturbances Mehanna et al. Park Rel Dis 2014; 20: Pagano et al. Neurology 2016; 86: 1 8 Wickremaratchi et al. Eur J Neurol 2009; 16: How is PD different for younger adults? Psychosocial effects more likely to become unemployed or retire early negative effects on finances, role functioning, social contacts, self-esteem experience more family and marital problems have higher depression scores rate their quality of life as worse than do patients with older onset with similar disease severity may need more support of family members Schrag A, et al. Mov Disord 2003; 18: Schrag A, Schott J. Lancet Neurol 2006; 5: Pathology Gross: Pallor of substantia nigra Microscopic: Loss of > 50% of substantia nigra neurons In surviving neurons, cytoplasmic inclusions called Lewy bodies Lewy bodies contain α-synuclein Loss of substantia nigra neurons results in loss of dopamine in nigrostriatal tract

9 Lewy Body A Chemical Balancing Act In the basal ganglia, dopamine is in dynamic equilibrium with acetylcholine Dopamine Acetylcholine Antiparkinsonian drugs either compensate for missing dopamine, or antagonize acetylcholine Currently Available Medications Anticholinergics Amantadine Carbidopa/Levodopa Dopamine agonists MAO (monoamine oxidase) inhibitors COMT (catechol-o-methyl transferase) inhibitors

10 Anticholinergic Drugs Trihexyphenidyl (Artane ) preferred by movement disorder specialists due to lower rate of sedation Benztropine (Cogentin ) Diphenhydramine (Benadryl ) all available as generics Anticholinergic Drugs Good for relief of tremor, little else The most notorious for causing cognitive side effects (memory loss, psychosis, confusion) Poorly tolerated by elderly patients Also cause dry mouth, blurred vision, other antimuscarinic effects Main indication: for young patients (< 60 years) whose predominant symptom is resting tremor Amantadine Antiviral drug with uncertain mechanism of antiparkinsonian effect Hubsher G, et al. Neurology 2012; 78: Modest benefit for all symptoms Second worst for causing cognitive effects Other adverse effects: Dry mouth Livedo reticularis Pedal edema

11 Case Presentation - 3 Our patient initially declined any symptomatic treatment After 6 months, she reported an increase in slowness with activities of daily living A trial of amantadine 100 mg b.i.d. produced satisfactory improvement Case Presentation - 4 Our patient reported increased symptoms 6 months later These responded to an increase in amantadine to 100 mg t.i.d. However, she soon developed swelling of her legs associated with a mottled appearance of her skin Amantadine was discontinued Amantadine One option for patients with mild symptoms May have more prolonged benefit than generally acknowledged Effective symptomatic treatment for levodopa-induced dyskinesias

12 Levodopa Marketed in U.S.A. in combination with carbidopa as Sinemet to reduce nausea Carbidopa has no anti-pd effect; pure antinauseant 1975: Sinemet = sine + emesis Initially formulated in carbidopa/levodopa ratio of 1:10 Now the standard ratio is 1:4 Current U.S.A. Formulations Sinemet (carbidopa/levodopa tablets) ratios: 10/100, 25/100, 25/250 Sinemet CR (controlled-release carbidopa/levodopa tablets) ratios: 25/100, 50/200 Parcopa (orally disintegrating carbidopa/levodopa tablets) ratios: 10/100, 25/100, 25/250 Stalevo (carbidopa/levodopa tablets plus entacapone): 12.5/50/200, 18.75/75/200, 25/100/200, 31.25/125/200, 37.5/150/200, 50/200/200 Rytary (capsules contain both immediate-release and extended-release beads of carbidopa-levodopa): 23.75/95, 36.25/145, 48.75/195, 61.25/245 Duopa (enteral suspension of carbidopa-levodopa): 4.63/20 per ml (in cartridges of 100 ml) Benefits of Levodopa The most effective drug in the treatment of motor manifestations of PD the cornerstone of treatment of PD for >40 years Virtually all (94%) patients with confirmed PD experience clinically significant benefit Associated with reduced disability compared to the pre-levodopa era Possibly associated with decreased mortality compared to the pre-levodopa era

13 Micrographia response to levodopa : Sinemet 25/100 two tablets t.i.d. Limitations of Levodopa Only one common early side effect: nausea Two problems with levodopa as PD progresses: 1. Fluctuations in symptom severity due to premature wearing off of benefit prior to the next dose 2. Involuntary movements (dyskinesias) Both fluctuations and dyskinesias are more common in younger patients Dopamine Agonists Act by direct stimulation of the postsynaptic dopamine receptors Molecular structure similar to dopamine Effective against most principal PD manifestations Tremor Akinesia Rigidity

14 Dopamine Agonists Currently available in the U.S.A.: Pramipexole (Mirapex ): 3 times a day extended-release (Mirapex ER ): once daily Ropinirole (Requip ): 3 times a day extra-long-acting (Requip XL ): pill once daily Apomorphine (Apokyn ): injectable as needed Rotigotine (Neupro ): skin patch once daily Micrographia response to medication January 2009 Prior to treatment August 2010 Ropinirole XL 8 mg daily Levodopa vs. Dopamine Agonists Side Effects Levodopa Nausea Dyskinesias Fluctuations Dopamine agonists Hallucinations/ psychosis Sedation Impulse-control disorders Edema Orthostatic hypotension

15 Dopamine Agonists Two main concerns with long-term dopamine agonist therapy: Sudden sleep attacks, concern with driving Impulse-control disorders Gambling Compulsive buying Hypersexuality, promiscuity Binge eating 17.1% on DA agonists vs. 6.9% not taking; OR 2.7 Weintraub et al. Arch Neurol 2010; 67: COMT & MAO-B Inhibitors Catechol-O-methyl transferase and Monoamine oxidase B enzymes break down dopamine Inhibitors of these enzymes allow dopamine molecules to survive longer Useful in patients with PD experiencing end-ofdose wearing off with levodopa Side effects similar to increasing levodopa MAO-B Inhibitors Selegiline (Eldepryl ) One size: 5 mg, max 5 mg b.i.d.; generic available Very modest symptomatic benefit Initially thought that selegiline slows progression in PD, but later disproved Orally dissolving selegiline (Zelapar ) 1.25 mg Rasagiline (Azilect ) 0.5 mg or 1 mg; once-a-day dosing, generic not available yet Many times more potent than selegiline Effective treatment for motor fluctuations Also approved for solo use

16 COMT Inhibitors Tolcapone (Tasmar ) Three doses daily More potent than entacapone Requires liver function monitoring Entacapone (Comtan ) 200 mg taken with each dose of levodopa Less effective than tolcapone No laboratory surveillance required Available in combination with carbidopa/levodopa (Stalevo ) Initial Pharmacologic Treatment - Mainstream Approach - Use anticholinergics, amantadine or rasagiline for milder symptoms Use levodopa or dopamine agonists when disability occurs Under 60 years old Maximize use of non-dopaminergic drugs Use dopamine agonists before levodopa Over 70 years old, prefer levodopa Long-Term Pharmacologic Treatment Principles Use minimum dose that provides satisfactory benefit TIP: In general, use small doses of multiple drugs, rather than large doses of any single drug Polypharmacy has become the norm in PD Lack of drug interactions permits this At each visit, be attentive to: Possible side effects Gaps of time in symptom relief Non-motor complications

17 Case Presentation - 5 Off amantadine, our patient felt severely impaired, and her tremor was more prominent than ever Due to her age (still under 60), she began pramipexole At a dose of pramipexole 1 mg t.i.d., she did well for 2 years After 2 years, she required the addition of Sinemet She said she had trouble tolerating Sinemet initially, especially the morning dose A pharmacy brochure had instructed her to take it on an empty stomach, and she became violently ill Management of PD Complications in Younger Adults Motor Fluctuations 1. Shorten levodopa dose interval, or increase dose quantity 2. Extended-release levodopa preparations 3. Protein redistribution diet 4. Increase/add dopamine agonist 5. Add COMT inhibitor; MAO-B inhibitor 6. Amantadine 7. Surgical approaches Management of PD Complications in Younger Adults Peak-Dose Dyskinesias 1. Reduce levodopa dose 2. Reduce or eliminate levodopa boosters MAO and COMT inhibitors 3. Substitute for levodopa with other antiparkinsonian medications 4. Trial of amantadine 5. DBS Surgery

18 Deep Brain Stimulation (DBS) Current surgical procedure of choice for PD Reduces patients dependence on medication Provides more consistent symptom control Does not produce benefit beyond the best results from medication, except for tremor Deep Brain Stimulation (DBS) Current surgical procedure of choice for PD Reduces patients dependence on medication Provides more consistent symptom control Does not produce benefit beyond the best results from medication, except for tremor Patients most likely to benefit from DBS: Young Tolerate surgery better, longer benefit Suffering from dyskinesias and fluctuations Tremor unresponsive to medication Duopa Surgical Enhancement of Medication Delivery Carbidopa/levodopa enteral suspension Administered directly into the small intestine via PEG- J (percutaneous endoscopic gastrostomy with jejunal extension) Pump provides continuous levodopa supply for 16 hours At night, pump disconnected and patients take oral meds Indicated for treatment of motor fluctuations

19 Other Treatment Options Hypophonia Lee Silverman Voice Therapy Balance Physical therapy specialists Common PD Management Issue Sudden Deterioration! In parkinsonism (motor function) or In cognitive function (confusion, hallucinations) Parkinson s disease is slowly progressive Sudden deterioration indicates a superimposed condition Most likely: urinary tract infection, often asymptomatic Also: other infections, new medications Parkinson s Disease in General Medicine

20 Prediagnostic PD in Primary Care Prediagnostic presentations of Parkinson s disease in primary care: a case-control study Schrag A, et al. Lancet Neurol 2014; 14: Retrospective database review of 8,166 with PD vs. 46,755 non-pd 5 years prior to dx, higher incidence in future PD patients of: tremor, balance impairments, constipation, hypotension, erectile dysfunction, urinary dysfunction, dizziness, fatigue, depression, and anxiety 10 years prior to dx, higher incidence in future PD patients of: tremor, constipation Autonomic Dysfunction Cardiovascular dysfunction Gastrointestinal dysfunction Genitourinary dysfunction Sweating dysfunction Autonomic - Cardiovascular Blood pressure instability Wide swings in BP throughout the day often spiking over 200 systolic BP fluctuation > 100 mmhg observed in 64.9% of PD patients (by ambulatory monitoring) Tsukamoto et al. Brain and Behavior 2013; 3: Nighttime hypertension Long-term trend toward low BP Mandates to control high BP cause physicians to treat minor cases leading to more frequent bouts of low BP

21 Autonomic - Cardiovascular As PD progresses, watch for: Resolution of prior hypertension Orthostatic hypotension Drugs for PD, esp. dopamine agonists, can aggravate the tendency to low BP Postprandial hypotension Syncope BP Target Recommendation The risks of supine hypertension in this setting are largely statistical and long-term, whereas those of orthostatic hypotension are real and immediate. Therefore, at our centre, we set a goal of a systolic blood pressure while standing of at least 100 mm Hg, in the morning. Goldstein D. Compr Physiol 2014; 4: Autonomic - Gastrointestinal - Constipation - The most common autonomic complication of PD Increased colonic transit time may worsen with disease progression Contributing factors Physical inactivity Delayed stomach transit Diminished fluid intake Some antiparkinsonian medications

22 Autonomic - Genitourinary Bladder Storage failure Urinary urgency Urinary frequency Urinary incontinence Bladder Voiding failure Urinary retention, may lead to infection Impotence Medical Comorbidities of PD Bone metabolism and joint diseases Osteoporosis 25-hydroxy-vitamin D3 deficiency Fractures Especially increased risk of hip/femoral fracture Frozen shoulder Low back pain Spinal deformity (camptocormia, Pisa syndrome) Poorer outcomes from shoulder and hip surgery Medical Comorbidities of PD Cancer Overall lower incidence of, and mortality from, cancer in PD Strong association: melanoma Higher risk in both patients and relatives Also increased risk: prostate, thyroid Reduced risk: colorectal, lung, pancreas, stomach

23 Medical Comorbidities of PD Other comorbidities Traumatic injuries other than fractures Deep vein thrombosis Associated with wheelchair use and postural abnormalities Malnutrition Medical Side Effects of PD Medications Orthostatic hypotension: dopamine agonists Peripheral edema: dopamine agonists, amantadine Nausea: levodopa Diarrhea: COMT inhibitors Constipation: anticholinergics Urinary retention: anticholinergics Common Errors in PD Management Levodopa Formulations A patient started Sinemet 25/100 and developed nausea. He was switched to the lower dose of Sinemet 10/100. The second number in carbidopa/levodopa formulations lists the mg content of the active ingredient (levodopa); the first is carbidopa Carbidopa is added to levodopa only to reduce nausea Thus switching a patient from 25/100 to 10/100 does not represent a lower dose of antiparkinsonian medication Paradoxically, patients suffer more side effects from 10/100 tablets than 25/100 tablets

24 Common Errors in PD Management Instigation of Nausea A patient started Sinemet 25/100. She followed the pharmacy directive not to take the medication with food. She developed nausea. Pharmacies often take a one-size-fits-all approach to PD Interference from protein is only a significant consideration in patients with dose-related fluctuations Instruct patients to ignore any pharmacy directive that contradicts your recommendation to take Sinemet with food at the beginning Common Errors in PD Management Treatment of Nausea A patient started Sinemet 25/100 and developed nausea. He was prescribed metoclopramide (Reglan ). Metoclopramide, prochlorperazine (Compazine ) and other antinauseants are dopamine receptor blockers. They aggravate PD. 4 remedies for nausea caused by levodopa Initiate carbidopa/levodopa after meals Take extra carbidopa 25 mg tablets Ondansetron (Zofran ); inactive at dopamine receptors Definitive Rx: domperidone (not dispensed in U.S.A.) Common Errors in PD Management Treatment of Hallucinations A patient began seeing people in the house who were not there. A physician prescribed risperidone. Risperidone, haloperidol, and most other antipsychotics are dopamine receptor blockers. They aggravate PD. Consider the following sequence of interventions Look for evidence of occult infection, especially UTI Withdraw anticholinergics, then amantadine, then dopamine agonists Prescribe a cholinesterase inhibitor (rivastigmine, donepezil)* Consider quetiapine or clozapine for an antipsychotic *Off-label

25 Lifestyle Intervention Physical Activity Physical activity: all forms are beneficial for PD patients Exercise Traditional, especially stretching Tai chi, yoga Dance (tango, ballroom, Irish set dancing, etc.) Sports (cycling, boxing, kayaking) Patients should be told: Exercise/activity is as important for PD as taking meds So find something they are willing to do regularly, and do it! Exercise, dance, sports, voice classes 5 days/week All led by certified instructors Support groups for patient and partners Bimonthly lectures by physicians and other professionals And much more all free of charge! Check us out at beinmotion.org Conveniently located near I-480 and I-271

26 Recommended Reading Calne S, Kumar A. Young onset Parkinson s disease: Practical management of medical issues. Parkinsonism and Related Disorders 2008; 14: Calne S, et al. Psychosocial issues in youngonset Parkinson s disease: Current research and challenges. Parkinsonism and Related Disorders 2008; 14:

Parkinson s Disease and Treatment Options for the Younger Adult

Parkinson s Disease and Treatment Options for the Younger Adult The Way CME Should Be Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning

More information

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug

More information

Optimizing Clinical Communication in Parkinson s Disease:

Optimizing Clinical Communication in Parkinson s Disease: Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of

More information

Best Medical Treatments for Parkinson s disease

Best Medical Treatments for Parkinson s disease Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells

More information

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical

More information

Parkinson s Disease Medications: Professionals Edition

Parkinson s Disease Medications: Professionals Edition Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu

More information

Medications used to treat Parkinson s disease

Medications used to treat Parkinson s disease Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John

More information

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,

More information

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10

More information

PARKINSON S MEDICATION

PARKINSON S MEDICATION PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development

More information

Treatment of Parkinson s Disease: Present and Future

Treatment of Parkinson s Disease: Present and Future Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing

More information

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing

More information

Evaluation of Parkinson s Patients and Primary Care Providers

Evaluation of Parkinson s Patients and Primary Care Providers Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,

More information

Key Concepts and Issues in Parkinson s Disease in 2016

Key Concepts and Issues in Parkinson s Disease in 2016 Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern

More information

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms. Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor

More information

Parkinson s Disease Current Treatment Options

Parkinson s Disease Current Treatment Options Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority

More information

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease. Sirilak yimcharoen Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically

More information

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease 5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater

More information

10th Medicine Review Course st July Prakash Kumar

10th Medicine Review Course st July Prakash Kumar 10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS

More information

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually

More information

Medication Management & Strategies When the levodopa honeymoon is over

Medication Management & Strategies When the levodopa honeymoon is over Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa

More information

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone

More information

Evaluation and Management of Parkinson s Disease in the Older Patient

Evaluation and Management of Parkinson s Disease in the Older Patient Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of

More information

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed

More information

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age

More information

PD: Key Treatment Considerations

PD: Key Treatment Considerations PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment

More information

Faculty. Joseph Friedman, MD

Faculty. Joseph Friedman, MD Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute

More information

Prior Authorization with Quantity Limit Program Summary

Prior Authorization with Quantity Limit Program Summary Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.

More information

9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations

9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations Parkinson s Disease Update Clinical and Operational Considerations Dana Saffel, PharmD, BCGP, CPh, FASCP President, CEO PharmaCare Strategies, Inc. September 2018 Objectives Describe epidemiology and pathophysiology

More information

Communicating About OFF Episodes With Your Doctor

Communicating About OFF Episodes With Your Doctor Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom

More information

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Update Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Progressive, chronic, neurodegenerative disease Slow,

More information

What s new for diagnosing and treating Parkinson s Disease?

What s new for diagnosing and treating Parkinson s Disease? What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology

More information

Parkinson s Disease Update

Parkinson s Disease Update Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms

More information

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological

More information

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS

More information

Welcome and Introductions

Welcome and Introductions Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1

More information

8/28/2017. Behind the Scenes of Parkinson s Disease

8/28/2017. Behind the Scenes of Parkinson s Disease BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic

More information

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following: 1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing

More information

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:

More information

Understanding Parkinson s Disease Important information for you and your loved ones

Understanding Parkinson s Disease Important information for you and your loved ones Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson

More information

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain. Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:

More information

ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO?

ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO? ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO? You may have noticed a change... Levodopa is a common treatment for Parkinson s, and doctors have relied on it for decades. Over time as Parkinson s progresses,

More information

Issues for Patient Discussion

Issues for Patient Discussion onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize

More information

Alison Charleston 1 st September 2016

Alison Charleston 1 st September 2016 Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence

More information

What is Parkinson s Disease?

What is Parkinson s Disease? 2018 Update in Parkinson s Disease: Treatments and Future Plans Arita McCoy, MSN, CRNP Johns Hopkins Parkinson s Disease and Movement Disorder Center A National Parkinson Foundation Center of Excellence

More information

Enhanced Primary Care Pathway: Parkinson s Disease

Enhanced Primary Care Pathway: Parkinson s Disease Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered

More information

Drugs for Parkinson s Disease

Drugs for Parkinson s Disease This Clinical Resource gives subscribers additional insight related to the Recommendations published in July 2017 ~ Resource #330705 Drugs for Parkinson s Disease Parkinson s disease is characterized by

More information

Non-Motor Symptoms of Parkinson s Disease

Non-Motor Symptoms of Parkinson s Disease Non-Motor Symptoms of Parkinson s Disease Samantha Holden, MD University of Colorado Movement Disorders MOTOR SYMPTOMS Rigidity Bradykinesia Tremor Gait Imbalance NON-MOTOR SYMPTOMS Dementia Urinary frequency

More information

Parkinson s Disease. Gillian Sare

Parkinson s Disease. Gillian Sare Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there

More information

Welcome and Introductions

Welcome and Introductions Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing

More information

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even

More information

Movement Disorders: A Brief Overview

Movement Disorders: A Brief Overview Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance

More information

Commonly encountered medications and their side effects - what the generalist needs to know

Commonly encountered medications and their side effects - what the generalist needs to know Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and

More information

Date of Referral: Enhanced Primary Care Pathway: Parkinson s Disease

Date of Referral: Enhanced Primary Care Pathway: Parkinson s Disease Specialist LINK Linking Physicians CALGARY AND AREA Patient Name: Date of Birth: Calgary RHRN: PHN / ULI: Date of Referral: Referring MD: Fax: Today s Date: CONFIRMATION: TRIAGE CATEGORY: REFERRAL STATUS:

More information

Motor Fluctuations in Parkinson s Disease

Motor Fluctuations in Parkinson s Disease Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations

More information

The Fresco Institute for Parkinson's and Movement Disorders

The Fresco Institute for Parkinson's and Movement Disorders The Fresco Institute for Parkinson's and Movement Disorders Follow Up Patient Questionnaire Name: Date: Accompanied by: Do you smoke? CURRENT PAST NEVER Which neurological symptom bothers you most right

More information

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor Parkinson s Disease History of Parkinson s It s much more than tremor Laura Dixon, DNP, MPA, APRN, FNP-BC University of Louisville Department of Neurology Movement Disorders Division Parkinson s Disease

More information

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and

More information

MEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension

MEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension MEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension Read this Medication Guide before you start using DUOPA and each time you get a refill. There may be new information. This

More information

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1). Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,

More information

Drugs Affecting the Central Nervous System

Drugs Affecting the Central Nervous System Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease

More information

Parkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center

Parkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center Parkinsons Disease update Sindhu R Srivatsal MD MPH Virginia Mason Medical Center PARKINSONISM Vs PARKINSON S Parkinsonism Bradykinesia: slowness of movements (essential feature) PLUS one of Tremor: resting

More information

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd. Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed

More information

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease FPIN's Clinical Inquiries Treatment of Early Parkinson's Disease Clinical Question What is the best medical therapy for early Parkinson's disease? Evidence-Based Answer Treatment of early Parkinson's disease

More information

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE J O N AT H A N S Q U I R E S, M D, F R C P C C L I N I C A L I N S T R U C T O R, UBC F AC U L T Y O F M E D I C I N E P AC I F I C P AR K I N S

More information

Drugs used in Parkinsonism

Drugs used in Parkinsonism Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your

More information

Headway Victoria Epilepsy and Parkinson s Centre

Headway Victoria Epilepsy and Parkinson s Centre Headway Victoria Epilepsy and Parkinson s Centre Parkinson s Overview and Medication Shannon Oatway Community Education/ Awareness Coordinator What is Parkinson s Disease? The basics It is a chronic and

More information

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:

More information

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000

More information

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels

More information

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates Editor: Marsha K. Millonig, MBA, RPh President/CEO Catalyst Enterprises,

More information

Faculty Information 2/15/2013

Faculty Information 2/15/2013 Timothy Reilly, PharmD, BCPS, CGP, FASCP Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey tjreilly@pharmacy.rutgers.edu Faculty Information Presenter:

More information

Dr Barry Snow. Neurologist Auckland District Health Board

Dr Barry Snow. Neurologist Auckland District Health Board Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent

More information

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl

More information

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) 475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive

More information

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for

More information

Parkinson's Disease and how you can make a difference with medication

Parkinson's Disease and how you can make a difference with medication Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy

More information

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz Parkinson s Disease A Guide to Medical Treatment SEEd srl. All rights reserved Piazza Carlo Emanuele II, 19 10123 Torino, Italy Tel. 011.566.02.58

More information

PL CE LIVE July 2015 Forum

PL CE LIVE July 2015 Forum July 2015 PL CE LIVE Rachel Maynard, PharmD Associate Editor Pharmacist s Letter/Pharmacy Technician s Letter CE Information Pharmacist's Letter / Therapeutic Research Center is accredited by the Accreditation

More information

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Multiple choice questions: ANSWERS

Multiple choice questions: ANSWERS Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?

More information

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available

More information

Parkinson's Disease KP Update

Parkinson's Disease KP Update Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have

More information

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

TRANSPARENCY COMMITTEE OPINION. 18 March 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379

More information

Appendix 2: Admissions checklists for people with Parkinson s

Appendix 2: Admissions checklists for people with Parkinson s Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,

More information

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported

More information

Literature Scan: Anti-Parkinson s Agents

Literature Scan: Anti-Parkinson s Agents Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People

More information

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral

More information